Literature DB >> 23396084

Qualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments.

Ryan J Hansen1, Robin M Brown, Jirong Lu, Victor J Wroblewski.   

Abstract

The aim of this work was to develop and characterize an ELISA to measure free ligand concentrations in rat serum in the presence of a Fab to the same ligand. A variety of experiments were conducted to understand optimal assay conditions and to verify that only free ligand was detected. The parameters explored included sample incubation time on plate, the initial concentrations of Fab and ligand, and the pre-incubation time required for the Fab-ligand complex concentrations to reach equilibrium. We found the optimal experimental conditions to include a 10-minute on-plate incubation of ligand-containing samples, with a 24-hour pre-incubation time for test samples of Fab and ligand to reach equilibrium. An alternative approach, involving removal of Fab-ligand complexes from the solution prior to measuring concentrations of the ligand, was also used to verify that the assay only measured free ligand. Rats were dosed subcutaneously with Fab and the assay was used to demonstrate dose-dependent suppression of endogenous free ligand levels in vivo.

Entities:  

Keywords:  ELISA; Fab; PK/PD; antibody; free ligand

Mesh:

Substances:

Year:  2013        PMID: 23396084      PMCID: PMC3893239          DOI: 10.4161/mabs.23508

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  16 in total

1.  Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.

Authors:  E Adelroth; S Rak; T Haahtela; G Aasand; L Rosenhall; O Zetterstrom; A Byrne; K Champain; J Thirlwell; G D Cioppa; T Sandström
Journal:  J Allergy Clin Immunol       Date:  2000-08       Impact factor: 10.793

Review 2.  Antibody pharmacokinetics and pharmacodynamics.

Authors:  Evelyn D Lobo; Ryan J Hansen; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2004-11       Impact factor: 3.534

Review 3.  Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody.

Authors:  Wendy S Putnam; Jing Li; Jonas Haggstrom; Chee Ng; Saloumeh Kadkhodayan-Fischer; Melissa Cheu; Yamo Deniz; Henry Lowman; Paul Fielder; Jennifer Visich; Amita Joshi; Nelson Shasha Jumbe
Journal:  AAPS J       Date:  2008-08-07       Impact factor: 4.009

4.  Monoclonal antibody pharmacokinetics and pharmacodynamics.

Authors:  W Wang; E Q Wang; J P Balthasar
Journal:  Clin Pharmacol Ther       Date:  2008-09-10       Impact factor: 6.875

5.  Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.

Authors:  Philip J Lowe; Stacey Tannenbaum; Aurelie Gautier; Pablo Jimenez
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

6.  Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients.

Authors:  Paul M Beer; Susan J Wong; Amjad M Hammad; Naomi S Falk; Martin R O'Malley; Samira Khan
Journal:  Retina       Date:  2006-10       Impact factor: 4.256

7.  A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

Authors:  Naoto Hayashi; Yuko Tsukamoto; William M Sallas; Philip J Lowe
Journal:  Br J Clin Pharmacol       Date:  2006-11-10       Impact factor: 4.335

8.  The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.

Authors:  Alison M Betts; Tracey H Clark; Jianxin Yang; Judith L Treadway; Mei Li; Michael A Giovanelli; Yasmina Abdiche; Donna M Stone; Vishwas M Paralkar
Journal:  J Pharmacol Exp Ther       Date:  2010-01-20       Impact factor: 4.030

9.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.

Authors:  Joyce C Y Chan; Derek E Piper; Qiong Cao; Dongming Liu; Chadwick King; Wei Wang; Jie Tang; Qiang Liu; Jared Higbee; Zhen Xia; Yongmei Di; Susan Shetterly; Ziva Arimura; Heather Salomonis; William G Romanow; Stephen T Thibault; Richard Zhang; Ping Cao; Xiao-Ping Yang; Timothy Yu; Mei Lu; Marc W Retter; Gayle Kwon; Kirk Henne; Oscar Pan; Mei-Mei Tsai; Bryna Fuchslocher; Evelyn Yang; Lei Zhou; Ki Jeong Lee; Mark Daris; Jackie Sheng; Yan Wang; Wenyan D Shen; Wen-Chen Yeh; Maurice Emery; Nigel P C Walker; Bei Shan; Margrit Schwarz; Simon M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-14       Impact factor: 11.205

Review 10.  On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.

Authors:  Philip J Lowe; Stacey Tannenbaum; Kai Wu; Peter Lloyd; Jennifer Sims
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-12-29       Impact factor: 4.080

View more
  2 in total

1.  Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.

Authors:  Weirong Wang; Xiaofeng Wang; Rajitha Doddareddy; Damien Fink; Thomas McIntosh; Hugh M Davis; Honghui Zhou
Journal:  AAPS J       Date:  2013-11-28       Impact factor: 4.009

2.  Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum.

Authors:  Alexander Colbert; Amber Umble-Romero; Samantha Prokop; Ren Xu; John Gibbs; Susan Pederson
Journal:  MAbs       Date:  2014-04-16       Impact factor: 5.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.